You are here

  • Home
  • Archive
  • Volume 22, Issue 1
  • Weekly adalimumab significantly reduces the number of abscesses and inflammatory nodules in patients with moderate to severe hidradenitis suppurativa

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Weekly adalimumab significantly reduces the number of abscesses and inflammatory nodules in patients with moderate to severe hidradenitis suppurativa
  1. Jan Mekkes
  1. Correspondence to : Dr Jan Mekkes, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; j.r.mekkes{at}amc.uva.nl

https://doi.org/10.1136/ebmed-2016-110581

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016;375:422–34OpenUrl.

    Context

    Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease, characterised by the presence of inflamed nodules, abscesses, pustules, fistulas and scar tissue, usually located in the axillary and inguinal area. Treatment is difficult; most patients require a combination of surgical treatment and medical treatment. The clinical symptoms can be reduced considerably by using anti-inflammatory medication. Since 2001, several monoclonal antibodies have been tried in HS, including the tumour necrosis factor α (TNF-α) inhibitors infliximab, etanercept …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Ethics approval Local Ethical Committees.

    • Provenance and peer review Commissioned; internally peer reviewed.